Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Twitter: expediting critical research analysis

Klaus Metzeler • 1 Mar 2019
ISAL 2019
Acute Myeloid Leukemia General Leukemia

“Social media plays an ever increasing role in all aspects of modern day life, with healthcare and medical communication being no exception. We spoke to Twitter-user Klaus Metzeler, MD, of LMU Hospital Munich, Munich, Germany, about the role of social media for healthcare professionals and researchers. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Klaus Metzeler

A study investigating long-term survivorship outcomes in AML
3:30
A study investigating long-term survivorship outcomes in AML
Eva Telzerow et al. • 17 Mar 2025
The challenges with accurately diagnosing and risk-stratifying patients with MDS
4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
The role of NGS in MDS diagnosis
3:10
The role of NGS in MDS diagnosis
Klaus Metzeler • 16 Apr 2024
Pre-MDS states: novel therapeutic approaches, and determining appropriate trial endpoints
3:17
Pre-MDS states: novel therapeutic approaches, and determining appropriate trial endpoints
Klaus Metzeler • 5 May 2023

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals